A study published August 5 in Nature identifies ZFP36L2 as a critical protein that enables colorectal cancer cells to metastasize by hijacking the body’s tissue repair mechanisms, offering a potential target for new therapies.
The discovery centers on ZFP36L2, a protein described as a molecular switch
that regulates how cells respond to stress and repair damage. Researchers at Memorial Sloan Kettering Cancer Center (MSK) found that this protein plays a pivotal role in both normal tissue regeneration and the spread of colorectal cancer, according to a study published in Nature and detailed in News Medical.
How ZFP36L2 Controls Cellular Identity
In healthy intestines, ZFP36L2 acts as a regulatory checkpoint during tissue repair. When damage occurs, specialized intestinal cells enter a stressed state before reverting to stem cells to rebuild the lining. This process is critical for maintaining gut health, but cancer cells exploit it to survive and spread, the research shows.
When a cell is stressed, there's no way it can reinvent itself or go back to its normal state,
explains Karuna Ganesh, MD, PhD, a senior author of the study. ZFP's function is to ensure balance in the system—it's important for the alarm to be sounded, but if it goes on too long, the system will be overwhelmed.
The protein works by degrading messenger RNAs that carry stress signals, effectively “turning off” the emergency response. Without ZFP36L2, mice struggled to recover from gut injuries, as their cells could not complete the transition back to a stem cell state. This mechanism, the researchers found, is similarly vital for cancer cells to establish metastases in distant organs.
Cancer’s Exploitation of the Stress Response
Colorectal cancer cells mimic the stress response triggered by tissue damage to survive metastasis. When tumor cells break away from a primary tumor, they enter a stressed state akin to injured gut cells. To form new tumors in the liver or lungs, they must suppress this stress response and revert to a stem cell-like state, a process dependent on ZFP36L2.
Our findings suggest that if ZFP can be disrupted in metastatic cancer cells, it could compromise their ability to start new tumors in other parts of the body,
says Quingwen “Karen” Jiang, PhD, lead author of the study. Experiments with patient-derived organoids showed that depleting ZFP36L2 significantly reduced the ability of cancer cells to form metastases, even when primary tumors were comparable in size.
The study used organoids from two primary tumors and two metastases, with results validated through single-cell RNA sequencing (scRNA-seq) and whole-exome sequencing (WES). These methods revealed that ZFP36L2’s role in stress adaptation extends beyond colorectal cancer, suggesting potential implications for other cancer types.
Technical Insights From the Study
The Nature study analyzed scRNA-seq data from 25 patient-matched primary tumor and liver metastasis samples, identifying 38,272 cells across multiple intestinal cell types. Researchers observed that ZFP36L2 activity declines as cells mature, acting as a molecular dimmer switch
to lock them into specialized roles.
Using the TEMPO pipeline for WES analysis, the team found that ZFP36L2 mutations were linked to altered stress response pathways in cancer cells.
What This Means for Future Treatments
The research highlights ZFP36L2 as a potential therapeutic target. By blocking its function, scientists may be able to prevent cancer cells from adapting to stress and forming new tumors. However, the study also underscores the complexity of the protein’s role: while it is essential for tissue repair, its overactivity could contribute to cancer progression.
ZFP’s function is to ensure balance in the system—it's important for the alarm to be sounded, but if it goes on too long, the system will be overwhelmed,
Ganesh notes. This dual role suggests that therapies targeting ZFP36L2 must carefully navigate the line between suppressing cancer and preserving normal tissue function.
Unanswered Questions and Next Steps
While the study provides a detailed roadmap of ZFP36L2’s mechanisms, several questions remain. How broadly applicable is this pathway across different cancer types? Can ZFP36L2 be safely targeted without disrupting normal tissue repair? And what are the long-term effects of therapies that interfere with this protein?
Further research will need to explore these issues, with the hope that understanding ZFP36L2’s dual role could lead to more precise cancer treatments. For now, the findings offer a critical insight into how cancer cells exploit the body’s own repair systems—and a potential pathway to disrupt that process.
Related reading
